JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

Recurrent Classical Hodgkin Lymphoma Clinical Trial

— JeRiCHO  

Official title:

A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02164500
• Other study ID #: JeRiCHO
• Status: Completed
• Phase: Phase 2
• Start date: October 2015
• Est. completion date: May 17, 2019

Study information

• Verified date: April 2020
• Source: University of Cologne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Purpose of this trial is:

• to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL

• to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: May 17, 2019
• Est. primary completion date: May 17, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• relapsed or refractory HL

• ECOG <= 2,

• no major organ dysfunction

• written informed consent

Exclusion Criteria:

• history of another primary malignancy = 2 years

• female patients who are pregnant or breast feeding

• patients with a known history of HIV seropositivity

• chronic active hepatitis

Related Conditions & MeSH terms

• Hodgkin Disease
• Lymphoma
• Recurrent Classical Hodgkin Lymphoma

Intervention

Drug:
• Ruxolitinib

Locations

Country	Name	City	State
Germany	1st Dept. of Medicine, Cologne University Hospital	Cologne

Sponsors (1)

Lead Sponsor	Collaborator
University of Cologne

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall response rate		8 weeks

External Links

•   Homepage GHSG